<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: Assess safety and glycaemic control in patients initiating insulin with, or switching from basal insulin to, biphasic insulin aspart 30/70 (BIAsp 30) in primary care in Finland </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: A non-randomised, non-interventional, open-label, 26-week study of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (T2D) patients prescribed BIAsp 30 by their physician, who determined starting dose, titration and injection frequency </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: 496 patients provided safety data (insulin-naïve n=197; prior insulin n=299 [84.9% received <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e> insulin]) </plain></SENT>
<SENT sid="3" pm="."><plain>Three patients (0.6%) reported four SADRs (three <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e>, one <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> with unconsciousness) </plain></SENT>
<SENT sid="4" pm="."><plain>HbA1c was significantly (p&lt;0.0001) reduced after 26 weeks' BIAsp 30 therapy (final dose): insulin-naïve -1.4% (44.4 IU); prior insulin -1.1% (77.4 IU) </plain></SENT>
<SENT sid="5" pm="."><plain>HbA1c&lt;7.0% was achieved by 10% of insulin-naïve patients at baseline and 51% at 26-week follow-up </plain></SENT>
<SENT sid="6" pm="."><plain>In the prior insulin group, 7% and 30% of patients had HbA1c&lt;7.0% at baseline and 26 weeks, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>Minor <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> increased significantly from baseline to study end: insulin-naïve 0.66-6.45 events/patient/year (p&lt;0.0001); prior insulin 5.11-8.58 events/patient/year (p&lt;0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>Weight increased by 1.0 kg (insulin-naïve) and 1.3 kg (previous insulin) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: BIAsp 30, initiated and titrated in T2D patients in primary care in Finland, showed a good safety profile and significantly improved glycaemic control </plain></SENT>
</text></document>